Eleven Biotherapeutics To Present Clinical Data On Lead Drug Candidate, EBI-005

Published: Nov 12, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, a biopharmaceutical company creating and developing protein therapeutics to treat diseases of the eye, announced today that clinical data on its lead drug candidate, EBI-005, will be presented at the 2013 Fall Educational Symposium taking place November 16, 2013 in New Orleans, LA. The symposium runs concurrent with the American Academy of Ophthalmology Annual Meeting also in New Orleans, LA. In the presentation entitled “Safety and Efficacy of a Novel Topical IL-1 Receptor Inhibitor in the Treatment of Patients with Moderate to Severe Dry Eye Disease,” which takes place at 3:30 p.m., Michael Goldstein, MD, the head of medical research for Eleven Biotherapeutics, will discuss Phase 1b/2a clinical results with EBI-005 in the treatment of moderate to severe dry eye disease (DED). Based on these results, Eleven Biotherapeutics plans to advance EBI-005 into pivotal Phase 3 clinical development in patients with moderate to severe DED.

Help employers find you! Check out all the jobs and post your resume.

Back to news